Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis.

O'Leary, C; Greer, R; Huggett, G; Good, P; Gurgenci, T; Hardy, J

Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis.

O'Leary, C Greer, R Huggett, G Good, P

Gurgenci, T Hardy, J

Permalink

Publisher:: BMJ PUBLISHING GROUP
Publication Type:: Journal Article
Citation:: BMJ Support Palliat Care, 2024, 14, (2), pp. 191-194
Issue Date:: 2024-05-17

Closed Access

	Filename	Description	Size
	191.full.pdf	Published version	445.13 kB		View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	O'Leary, C
dc.contributor.author	Greer, R
dc.contributor.author	Huggett, G
dc.contributor.author	Good, P https://orcid.org/0000-0002-8198-0375
dc.contributor.author	Gurgenci, T
dc.contributor.author	Hardy, J
dc.date.accessioned	2024-10-09T03:42:41Z
dc.date.available	2024-01-22
dc.date.available	2024-10-09T03:42:41Z
dc.date.issued	2024-05-17
dc.identifier.citation	BMJ Support Palliat Care, 2024, 14, (2), pp. 191-194
dc.identifier.issn	2045-435X
dc.identifier.issn	2045-4368
dc.identifier.uri	http://hdl.handle.net/10453/181327
dc.description.abstract	OBJECTIVES: Medical cannabinoids have become increasingly popular over the last decade. Preclinical trials suggest cannabinoids, for example, cannabidiol (CBD), may provide an anticancer effect; however, good-quality clinical information supporting this is lacking. We assessed the effect of CBD treatment on disease progression and survival in patients enrolled in a study of CBD versus placebo for symptom management in patients with advanced cancer (MEDCAN-1). METHODS: We reviewed the clinical records of all patients enrolled in the MEDCAN-1 Study (CBD vs placebo) at days 14, 28 and 56 of study follow-up, for evidence of disease progression. The proportion of participants with disease progression by treatment arm at each time point was compared, as was survival between both groups from study entry to the censor date (end of study period) and the effect of treatment arm and disease progression status on survival. RESULTS: Of the 135 patient records assessed, 128 were included in the final analysis. 36% (n=46) had progressive disease documented at day 28, rising to 49.2% (n=63) by day 56. No significant difference in disease progression was noted between the two groups at days 14 (p=0.33), 28 (p=0.67) or 56 (p=0.50). There was no difference in survival between both groups from study entry to censor date (p=0.38). Disease progression at day 14 was highly predictive of mortality (p<0.001). CONCLUSIONS: In this substudy analysis, treatment with CBD oil did not affect disease progression or survival over the course of 56 days in patients with advanced cancer.
dc.format	Electronic
dc.language	eng
dc.publisher	BMJ PUBLISHING GROUP
dc.relation.ispartof	BMJ Support Palliat Care
dc.relation.isbasedon	10.1136/spcare-2023-004746
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1110 Nursing, 1117 Public Health and Health Services
dc.subject.classification	4203 Health services and systems
dc.subject.classification	4205 Nursing
dc.subject.mesh	Humans
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Neoplasms
dc.subject.mesh	Disease Progression
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Aged
dc.subject.mesh	Adult
dc.subject.mesh	Humans
dc.subject.mesh	Neoplasms
dc.subject.mesh	Disease Progression
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Adult
dc.subject.mesh	Aged
dc.subject.mesh	Middle Aged
dc.subject.mesh	Female
dc.subject.mesh	Male
dc.subject.mesh	Humans
dc.subject.mesh	Cannabidiol
dc.subject.mesh	Neoplasms
dc.subject.mesh	Disease Progression
dc.subject.mesh	Male
dc.subject.mesh	Female
dc.subject.mesh	Middle Aged
dc.subject.mesh	Aged
dc.subject.mesh	Adult
dc.title	Cannabidiol oil or placebo in advanced cancer-disease progression and survival: a secondary analysis.
dc.type	Journal Article
utslib.citation.volume	14
utslib.location.activity	England
utslib.for	1110 Nursing
utslib.for	1117 Public Health and Health Services
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Health
utslib.copyright.status	closed_access	*
dc.date.updated	2024-10-09T03:42:39Z
pubs.issue	2
pubs.publication-status	Published online
pubs.volume	14
utslib.citation.issue	2

Abstract:

OBJECTIVES: Medical cannabinoids have become increasingly popular over the last decade. Preclinical trials suggest cannabinoids, for example, cannabidiol (CBD), may provide an anticancer effect; however, good-quality clinical information supporting this is lacking. We assessed the effect of CBD treatment on disease progression and survival in patients enrolled in a study of CBD versus placebo for symptom management in patients with advanced cancer (MEDCAN-1). METHODS: We reviewed the clinical records of all patients enrolled in the MEDCAN-1 Study (CBD vs placebo) at days 14, 28 and 56 of study follow-up, for evidence of disease progression. The proportion of participants with disease progression by treatment arm at each time point was compared, as was survival between both groups from study entry to the censor date (end of study period) and the effect of treatment arm and disease progression status on survival. RESULTS: Of the 135 patient records assessed, 128 were included in the final analysis. 36% (n=46) had progressive disease documented at day 28, rising to 49.2% (n=63) by day 56. No significant difference in disease progression was noted between the two groups at days 14 (p=0.33), 28 (p=0.67) or 56 (p=0.50). There was no difference in survival between both groups from study entry to censor date (p=0.38). Disease progression at day 14 was highly predictive of mortality (p<0.001). CONCLUSIONS: In this substudy analysis, treatment with CBD oil did not affect disease progression or survival over the course of 56 days in patients with advanced cancer.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/181327